Navigation Links
AmeriCares and AstraZeneca Work Together Delivering Critical Medicines to Help People Living with Chronic Diseases in the U.S.
Date:3/28/2011

STAMFORD, Conn., March 28, 2011 /PRNewswire-USNewswire/ -- AmeriCares and AstraZeneca have teamed to deliver critical medicines to help people living with chronic diseases throughout the United States. AstraZeneca has donated $5 million in cardiovascular and gastrointestinal medications to AmeriCares in support of its Domestic Medical Assistance Program.  The program delivers donated medicines and medical supplies to a network of more than 300 clinics treating the uninsured and underinsured.  Through the AstraZeneca donation, AmeriCares will be able to deliver prescription medications to more than 100 clinics across 38 states.  

"AmeriCares delivery of medical assistance has tripled in just the past two years alone," said Adam Zayan, M.D., vice president of programs at AmeriCares. "With clinics struggling to meet rising demands, this donation from AstraZeneca is crucial to helping people living with chronic diseases. We are so grateful to AstraZeneca for partnering with us so we can increase access to these vital medicines and help restore health to so many people in need throughout the country."

By working together, AmeriCares and AstraZeneca will help clinics across the United States treat patients suffering from chronic health conditions, including acid reflux, hypertension, high cholesterol and cardiovascular diseases, as well as helping to reduce complications stemming from diabetes. Since 2003, AstraZeneca donated essential medicines to AmeriCares valued at more than $63 million.

"Our medicines can only be effective if people have access to them, so these programs are essential," said Jennifer McGovern, director, patient assistance programs, AstraZeneca.

About AmeriCares

AmeriCares is a nonprofit global health and disaster relief organization which delivers medicines, medical supplies and aid to people in need around the world and across the United States.  Since it was established in 1982, AmeriCares has distributed more than $10 billion in humanitarian aid to 147 countries.  For more information, visit www.AmeriCares.org.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).

AZ&Me™ is a trademark of the AstraZeneca group of companies.

CONTACT: Donna Porstner

203-658-9579

dporstner@AmeriCares.org


'/>"/>
SOURCE AmeriCares
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AmeriCares Honors Cardinal Health with Power of Partnership Award
2. Medco Partners with AmeriCares to Rush Donated Medicines to Help Victims of the Haiti Earthquake
3. AmeriCares Delivering $1.5 Million in Aid for Libya Crisis
4. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
5. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
6. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
7. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
8. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
9. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
10. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
11. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
Breaking Medicine News(10 mins):